The investigational immunotherapy drug bintrafusp alfa (also called M7824), a bifunctional fusion protein, shrank the tumors of some patients with advanced HPV-related cancers, according to results from a phase 1 clinical trial.
from Cancer Currents: An NCI Cancer Research Blog http://bit.ly/2Wb6n5G